Newswise — When an opening or wound is created in the body—whether via surgery, trauma, biopsy, device implantation, or in consumer settings—a potential for detrimental bleeding exists. This potential is magnified if the patient is on antithrombotic therapy, commonly known as a blood thinner, such as antiplatelet or anticoagulant medication. The surgeon must manage and preferably prevent bleeding and leakage, as well as other challenges. Currently available tools for resolving these problems are often inadequate.
Dr. Terrence W. Norchi, the CEO of Arch Therapeutics, can discuss this need firsthand. He earned an MD degree from Northeast Ohio Medical University and completed his internal medicine residency in 1994 at Baystate Medical Center, Tufts University School of Medicine, where he was selected to serve as the Chief Medical Resident.
Under Dr. Norchi’s leadership, Arch is developing the AC5 Surgical Hemostatic Device™ and AC5 Topical Hemostatic Device™, which are both designed for controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care.
Arch recently reported data indicating that treatment with AC5™ achieved median time to hemostasis 41 percent faster than the standard of care during a dermatology procedure. Additional clinical data indicated that for a group of patients who were taking antiplatelet therapy, median time to hemostasis was also significantly reduced. In fact, in both groups, the time to hemostasis for wounds treated with AC5 was less than 30 seconds. This may help make surgery a more realistic option for those patients who should not stop taking their blood thinner for medical reasons, but for whom surgical procedures could lead to a risk of excessive bleeding.More About Dr. Terrence W. NorchiTerrence W. Norchi, MD is the co-founder, President and Chief Executive Officer of Arch Therapeutics. Prior to Arch, Dr. Norchi was portfolio manager of one of the world’s largest healthcare mutual funds and pharmaceutical analyst at Putnam Investments. Prior to that, he served as the senior global biotech and international pharmaceutical equity analyst at Citigroup Asset Management, and as a sell-side analyst covering non-U.S. pharmaceutical equities at Sanford C. Bernstein in New York City.
RSS